mutations, in whom rituximab seems to own tiny added price.59 Other genomic subgroups, such as clients with BIRC3translocations or amplifications in addition to the genomic alterations previously present in the initial CLL, but deficiency the common mutations noticed in Principal DLBCL indicating they may well correspond to a distinct biological cl